Nurix Therapeutics, Inc.

For the period ended Aug 31, 2026. Filed Oct 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Aug 31, 2026 · Filed Oct 13, 2026

NRIX$15.88-1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulated deficit · Totalstockholders’equity
Shares · Amount
Balance as of November 30, 2024	75,870,718	$76	$1,265,536	$150	$(738,769)	$526,993
Exercise of stock options	37,428	—	221	—	—	221
Vesting of restricted stock units	242,923	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	83,730	—	1,252	—	—	1,252
Stock-based compensation	—	—	8,726	—	—	8,726
Unrealized gain on available-for-sale marketable securities	—	—	—	76	—	76
Net loss	—	—	—	—	(56,351)	(56,351)
Balance as of February 28, 2025	76,234,799	76	1,275,735	226	(795,120)	480,917
Exercise of stock options	1,233	—	6	—	—	6
Vesting of restricted stock units	197,632	—	—	—	—	—
Stock-based compensation	—	—	10,390	—	—	10,390
Unrealized loss on available-for-sale marketable securities	—	—	—	(246)	—	(246)
Net loss	—	—	—	—	(43,464)	(43,464)
Balance as of May 31, 2025	76,433,664	$76	1,286,131	(20)	(838,584)	447,603
Exercise of stock options	18,822	1	177	—	—	178
Vesting of restricted stock units	311,485	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	108,715	—	977	—	—	977
Stock-based compensation	—	—	9,776	—	—	9,776
Unrealized gain on available-for-sale marketable securities	—	—	—	139	—	139
Net loss	—	—	—	—	(86,421)	(86,421)
Balance as of August 31, 2025	76,872,686	$77	$1,297,061	$119	$(925,005)	$372,252

Common stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Accumulateddeficit · Totalstockholders’equity
Shares · Amount
Balance as of November 30, 2025	101,807,484	$102	$1,541,766	$105	$(1,003,226)	$538,747
Issuance of common stock in “at the market” financing, net of issuance costs	1,000,000	1	17,993	—	—	17,994
Exercise of stock options	77,942	—	375	—	—	375
Vesting of restricted stock units	330,395	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	183,992	—	1,596	—	—	1,596
Stock-based compensation	—	—	9,404	—	—	9,404
Unrealized loss on available-for-sale marketable securities	—	—	—	(49)	—	(49)
Net loss	—	—	—	—	(87,174)	(87,174)
Balance as of February 28, 2026	103,399,813	103	1,571,134	56	(1,090,400)	480,893
Exercise of stock options	6,688	—	66	—	—	66
Vesting of restricted stock units	295,010	1	(1)	—	—	—
Stock-based compensation	—	—	11,404	—	—	11,404
Unrealized loss on available-for-sale marketable securities	—	—	—	(201)	—	(201)
Net loss	—	—	—	—	(89,535)	(89,535)
Balance as of May 31, 2026	103,701,511	104	1,582,603	(145)	(1,179,935)	402,627
Exercise of pre-funded warrants	4,708,290	5	(5)	—	—	—
Exercise of stock options	363,266	—	4,020	—	—	4,020
Vesting of restricted stock units	341,632	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	85,695	—	1,139	—	—	1,139
Stock-based compensation	—	—	10,783	—	—	10,783
Unrealized loss on available-for-sale marketable securities	—	—	—	(65)	—	(65)
Net income	—	—	—	—	549,807	549,807
Balance as of August 31, 2026	109,200,394	$109	$1,598,540	$(210)	$(630,128)	$968,311

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.